Drugs.com - Clinical Trials

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

DUBLIN--(BUSINESS WIRE) May 23, 2025 --Prothena Corporation plc (NASDAQ:PRTA) today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680)...

May 28, 2025 - 04:10
 0
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
DUBLIN--(BUSINESS WIRE) May 23, 2025 --Prothena Corporation plc (NASDAQ:PRTA) today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680)...
Read More

Tags:

Previous Article

Swiss watches see 18% shipping boom ahead of possible Trump tariffs

Next Article

The Woodside boss’s attacks on my generation are blatant scapegoating – and we s...

Related Posts

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Granted Three U.S. FDA Fast Track Designations...

May 12, 2025  0

Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Discontinues Development of Oral GLP-1 Receptor ...

May 12, 2025  0

Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-Daily Oral Pill for Obstructive Sleep Apnea

Apnimed Announces Positive Topline Results in the First...

May 20, 2025  0